Product

Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor

Aliases

Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)

1 clinical trial

1 indication

Indication

Advanced Solid Tumor Cancer

Clinical trial

A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors

Status: Recruiting, Estimated PCD: 2025-08-18